Maria Dêbiec‐Rychter

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne et al. · European Journal of Cancer · 2006 · 893 citations

Oncology, Gastrointestinal Oncology, Medicine +10

Toward Minimal Residual Disease-Directed Therapy in Melanoma

Florian Rambow, Aljosja Rogiers, Oskar Marín-Béjar et al. · Cell · 2018 · 731 citations · Full text

Novel Therapy, Medicine, Melanoma +4

NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines

George D. Demetri, Robert S. Benjamin, Charles D. Blanke et al. · Journal of the National Comprehensive Cancer Network · 2007 · 635 citations

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

Maria Dêbiec‐Rychter, Jan Cools, Herlinde Dumez et al. · Gastroenterology · 2005 · 492 citations · Full text

Pkc412 Inhibitor, Imatinib-resistant Mutants, Gastrointestinal Oncology +9

Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225

Grant A. McArthur, George D. Demetri, A. van Oosterom et al. · Journal of Clinical Oncology · 2005 · 477 citations